Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials

ConclusionThe higher range of the licensed dose achieves the optimal balance between efficacy, safety, and tolerability in patients with DS and LGS.Clinical trial registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023392454.
Source: Frontiers in Neurology - Category: Neurology Source Type: research